A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
NCT00835926
Completed
To describe the safety during days 0 to 21 following injection of the 2003-2004 formulation of the inactivated, split-virion influenza vaccine Fluzone® in subjects aged 18-59 years and subjects aged ≥ 60 years. To describe the immune response at 21 days following injection of the 2003-2004 formulation of the inactivated, split-virion influenza vaccine Fluzone®, in subjects aged 18-59 years and subjects aged ≥ 60 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2016
Locations: Not set, Norfolk, Virginia
Conditions: Influenza
Register for Updates
Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age
NCT00858468
Completed
Primary Objective: To describe the safety of the 2004-2005 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule (described in the package insert for vaccine-naïve young children) to the investigational and control groups. Observational Objective: To describe the percentage of protective Hemagglutination Inhibition (HAI) antibody titers (following a 2-dose Fluzone® immunization series) to each of the 3 vaccine antigens among the inve... Read More
Gender:
ALL
Ages:
Between 2 months and 9 months
Trial Updated:
04/12/2016
Locations: Not set, Little Rock, Arkansas +7 locations
Conditions: Influenza
Register for Updates
Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age
NCT00885105
Completed
The study is to compare the 2 Groups with respect to antibody responses to inactivated influenza vaccine. Observational Objectives: * To describe the percentage of participants with protective Hemagglutinin (HAI) antibody titers to each of the 3 vaccine antigens in both study groups following each vaccination. * To describe the HAI geometric mean titer (GMTs) to each of the 3 vaccine antigens in both study groups following each vaccination. * To describe the safety of the 2005-2006 pediatric f... Read More
Gender:
ALL
Ages:
Between 6 months and 11 months
Trial Updated:
04/12/2016
Locations: Not set, Little Rock, Arkansas +5 locations
Conditions: Influenza
Register for Updates
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
NCT00952419
Completed
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after each injection. * To describe the safety of the candidate vaccines after each injection.
Gender:
ALL
Ages:
Between 6 months and 9 years
Trial Updated:
04/12/2016
Locations: Not set, Miami Beach, Florida +19 locations
Conditions: Influenza, Swine-origin A/H1N1 Influenza
Register for Updates
Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM
NCT01011049
Completed
The purpose of this study is to generate additional data on the immunogenicity and safety of revaccination with Fluzone Intradermal (ID) or Fluzone Intramuscular (IM) vaccine. Primary Objective: * To evaluate and describe the safety profile of revaccination with Fluzone ID for all participants. Secondary Objective: * To describe immunogenicity following revaccination with Fluzone ID or Fluzone IM.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/12/2016
Locations: Not set, Hoover, Alabama +44 locations
Conditions: Influenza
Register for Updates
A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age
NCT01258595
Completed
The aim of the study is to generate data on key parameters associated with assessment of influenza vaccines in individuals 50-64 years of age Primary Objective: * To describe the immunogenicity of High-Dose Trivalent Inactivated Influenza Vaccine (TIV) compared to TIV. * To describe the safety profile of High-Dose Trivalent Inactivated Influenza Vaccine, as assessed by solicited adverse reactions collected for 7 days post-vaccination, and unsolicited adverse events (including Serious Adverse E... Read More
Gender:
ALL
Ages:
Between 50 years and 64 years
Trial Updated:
04/12/2016
Locations: Not set, Idaho Falls, Idaho +4 locations
Conditions: Influenza
Register for Updates
Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study
NCT02500511
Completed
To determine the persistence of protective antibody levels for subjects who seroconverted after vaccination with NmVac4-A/C/Y/W-135-DT™ Participants in trial # JN-NM-002, who seroconverted for serogroups A and C will be contacted and asked to provide a blood sample at 12-24 months after vaccination with NmVac4-A/C/Y/W-135-DT. Serum Bactericidal Assays will be performed to evaluated duration of protective antibody titer for NmVac4-A/C/Y/W-135-DT for all four serogroups. To determine if subjects... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/08/2016
Locations: IRC Clinics, Towson, Maryland
Conditions: Meningococcal Meningitis, Meningococcal Infections
Register for Updates
Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer
NCT00558051
Completed
The purpose of this study is to evaluate the administration, safety and immunologic effectiveness of an experimental vaccine for colorectal cancer patients.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/31/2016
Locations: University of Cancer Institute, Pittsburgh, Pennsylvania
Conditions: Metastatic Colorectal Cancer
Register for Updates
Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone
NCT01498718
Completed
This is a Phase 1b, randomized study in healthy younger (18-50 years) and older (51-70 years) adults to evaluate the safety, tolerability, and immunogenicity of a prime-boost vaccination regimen with an investigational plasmid DNA vaccine directed towards the 2011/12 influenza vaccine strains as a prime followed 36 weeks later by the 2012/13 influenza trivalent inactivated vaccine (TIV) as the booster injection, as compared to placebo prime followed by the 2012/13 seasonal TIV. The hypothesis is... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/23/2016
Locations: Hope Clinic of the Emory Vaccine Center, Decatur, Georgia +3 locations
Conditions: Influenza
Register for Updates
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
NCT00445523
Completed
Patients with metastatic renal cell cancer will be enrolled to receive either Trovax® alone or Trovax® plus Interferon Alfa. The study will try to determine whether the use of Trovax® will delay tumor progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2016
Locations: Baylor College of Medicine - Methodist Hospital, Houston, Texas
Conditions: Carcinoma, Renal Cell
Register for Updates
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
NCT00595920
Terminated
The purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.
Gender:
ALL
Ages:
All
Trial Updated:
02/16/2016
Locations: North Central Neurology Associates, PC, Cullman, Alabama +26 locations
Conditions: Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Register for Updates
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
NCT01629589
Completed
The aim of this study is to describe immunogenicity of a single booster dose of Adacel vaccine versus Boostrix vaccine among approximately 420 adolescents 11 to \<13 years of age. Primary objective: * To describe seroprotection rates against tetanus and diphtheria in subjects randomized to receive either Adacel or Boostrix vaccine. Observational objectives: * To describe pre- and post-vaccination tetanus, diphtheria, and pertussis geometric mean antibody concentrations (GMCs) in subjects ran... Read More
Gender:
ALL
Ages:
Between 11 years and 12 years
Trial Updated:
02/02/2016
Locations: Not set, Sacramento, California +7 locations
Conditions: Tetanus, Diphtheria, Pertussis, Whooping Cough
Register for Updates